DCTH Delcath stock news
On November 9, 2026, Delcath Systems, Inc. reported financial results for the third quarter ended September 30, 2026, and raised its full--year 2026 revenue guidance to $115 million–$117 million. Third--quarter revenue increased 71% year--over--year to $35.1 million, compared to $20.6 million in Q3 2025, driven by $32.7 million in HEPZATO KIT revenue and $2.4 million in CHEMOSAT revenue. Gross margin expanded to 89% from 87% in the prior--year period. Delcath posted net income of $7.0 million, up from $0.8 million in Q3 2025, with non--GAAP adjusted EBITDA reaching $11.5 million. Operating cash flow stood at $8.2 million, bringing total cash and investments to $104.3 million with zero debt. Operationally, the company expanded its commercial footprint to 33 active treatment centers.